Takeda

Debt-laden Takeda to sell OTC drugs in Middle East and Africa for $200m
Debt-laden Takeda to sell OTC drugs in Middle East and Africa for $200m
Pharmaforum
Takeda
Shire
M&A
Acino
Middle East
Africa
Flag link:
ImaginAb joins with AZ, Pfizer and Takeda to develop tumour imaging tech
ImaginAb joins with AZ, Pfizer and Takeda to develop tumour imaging tech
Pharmaforum
ImaginAb
tumor imaging
AstraZeneca
Pfizer
Takeda
Flag link:
Takeda breaks into top 20 largest pharmas with Shire merger
Takeda breaks into top 20 largest pharmas with Shire merger
Pharmaforum
Takeda
Shire
M&A
Flag link:
Goldfinch Bio, Takeda sign deal for CB1 monoclonal antibody to treat rare and metabolic kidney diseases
Goldfinch Bio, Takeda sign deal for CB1 monoclonal antibody to treat rare and metabolic kidney diseases
Pharmaceutical Business Review
Goldfinch Bio
Takeda
CB1 monoclonal antibodies
Flag link:
Takeda pens Prometheus pact to find novel IBD targets
Takeda pens Prometheus pact to find novel IBD targets
Fierce Biotech
Takeda
inflammatory bowel disease
R&D
Promethera Biosciences
Flag link:
Mom approved: J&J, Takeda and more lead Working Mother's best places to work list for 2019
Mom approved: J&J, Takeda and more lead Working Mother's best places to work list for 2019
Fierce Pharma
JNJ
Takeda
parents
Eli Lilly
Merck
Novo Nordisk
Sanofi
Flag link:
Takeda eyes emerging markets asset sale to trim its debt; report
Takeda eyes emerging markets asset sale to trim its debt; report
Pharmaforum
Takeda
Shire
M&A
emerging markets
Europe
Flag link:
Takeda recalls Natpara but warns patients not to abruptly stop treatment
Takeda recalls Natpara but warns patients not to abruptly stop treatment
Fierce Pharma
Takeda
Natpara
product recalls
drug manufacturing
Flag link:
Hospitals rationing immune disorder drug
Hospitals rationing immune disorder drug
Beckers Hospital Review
Human Immune Globulin Infusion
drug shortages
Pfizer
Takeda
Flag link:
Takeda, Sosei form gastrointestinal disease R&D pact
Takeda, Sosei form gastrointestinal disease R&D pact
Fierce Biotech
Takeda
Sosei Heptares
R&D
gastrointestinal disease
Flag link:
Takeda staffers accuse drugmaker of favoring Shire employees during merger: report
Takeda staffers accuse drugmaker of favoring Shire employees during merger: report
Fierce Pharma
Korea
Shire
Takeda
employees
M&A
Flag link:
Drugmakers will profit from climate change, Morgan Stanley says
Drugmakers will profit from climate change, Morgan Stanley says
Beckers Hospital Review
climate change
Morgan Stanley
Merck
Sanofi
vaccines
GSK
Takeda
JNJ
Moderna Therapeutics
Flag link:
As Takeda absorbs Shire’s R&D ops, the focus is on replacing a centralized command model with a ‘light touch’ in a restructured global organization
As Takeda absorbs Shire’s R&D ops, the focus is on replacing a centralized command model with a ‘light touch’ in a restructured global organization
Endpoints
Takeda
Shire
R&D
restructuring
M&A
Flag link:
Takeda Eyes Additional Divestitures to Pare Down Shire Deal Debt
Takeda Eyes Additional Divestitures to Pare Down Shire Deal Debt
BioSpace
Takeda
Shire
M&A
Flag link:
Takeda Receives 1st Stem Cell-Derived CAR-T From Kyoto University Collaboration
Takeda Receives 1st Stem Cell-Derived CAR-T From Kyoto University Collaboration
BioSpace
Takeda
Kyoto University
CAR-T
stem cells
Flag link:
Novartis wraps up acquisition of Takeda’s dry eye drug Xiidra
Novartis wraps up acquisition of Takeda’s dry eye drug Xiidra
Pharmaceutical Business Review
Novartis
Takeda
Xiidra
hdry eye disease
Flag link:
Takeda suffers another setback in its quest to expand myeloma drug’s reach — and blockbuster potential
Takeda suffers another setback in its quest to expand myeloma drug’s reach — and blockbuster potential
Endpoints
Takeda
Ninlaro
clinical trials
Flag link:
FDA approves GATTEX for children with short bowel syndrome
FDA approves GATTEX for children with short bowel syndrome
Pharmaceutical Business Review
Takeda
FDA
Gattex
short bowel syndrome
pediatrics
Flag link:
May 15 ASCO Quick Takes: After-hours pop for Iovance, MacroGenics; plus Takeda, Amgen, Forty Seven
May 15 ASCO Quick Takes: After-hours pop for Iovance, MacroGenics; plus Takeda, Amgen, Forty Seven
BioCentury
Iovance
LN-145
cervical cancer
Takeda
TAK-788
non-small cell lung cancer
Amgen
AMG-510
Macrogenics
margetuximab
HER2-positive metastatic breast cancer
Forty Seven
Flag link:
Takeda veterans, Frazier launch Phathom with $90M to develop GI drug vonoprazan
Takeda veterans, Frazier launch Phathom with $90M to develop GI drug vonoprazan
BioCentury
Takeda
Frazier Healthcare
Phathom
vonoprazan
gastrointestinal
Flag link:

Pages